×
Cuprina Holdings (Cayman) Limited is a Singapore-based micro-cap biomedical company focused on chronic wound care, listed on Nasdaq under the ticker CUPR. The stock has traded in a volatile range over the trailing 30 days, ending near $1.80 for a modest single-digit percentage decline that keeps the move below a sharp-swing threshold.
EMBC slipped from a prior close of $6.33 to $6.12, a decline of -3.32%, during regular trading hours. No verified news or fundamental catalyst found. The decline is consistent with the stock's normal trading pattern — it averages roughly a 3% absolute move per session and frequently swings by this much or more.
STAAR Surgical (STAA) fell -4.12% during regular trading, sliding from a $26.72 prior close to $25.62. The slide extends a fade from STAA's post-earnings pop: its Nov. 4 Q3 report beat on revenue and adjusted EBITDA but missed on GAAP EPS ($0.11 vs $0.19), showed gross margin slipping to 70.9%, and offered no guidance, so the initial +7.95% surge is now retracing.
Jin Medical International (ZJYL) is trading up +1.24%, rising from a prior close of $3.22 to $3.26 during regular market hours. No verified news or fundamental catalyst found for today's modest gain; the move is likely a continuation of the stock's speculative multi-day rally in a low-float, thinly traded micro-cap.
XRAY dropped from a previous close of $10.09 to $9.05, a -10.31% decline, during regular trading on November 6, extending steep after-hours losses. The drop extends a selloff sparked by Q3 2026 results released after the November 5 close: adjusted EPS of $0.29 missed estimates and management cut full-year adjusted EPS guidance to $1.20–$1.30 from $1.40–$1.50.
AtriCure (ATRC) shares slid from a prior close of $61.28 to $59.54 intraday, a decline of -2.84% during regular trading hours on Thursday. The pullback extends post-earnings profit-taking: after Nov 3's Q3 beat (adjusted EPS $0.18 and $154.5M revenue) sparked a +8.5% surge and a -6.5% reversal, today's move is continued consolidation with no fresh same-day catalyst.
Nephros reported third quarter 2026 net revenue of approximately $5.6 million , an 18% increase from $4.8 million in the prior-year period. Diluted earnings per share (EPS) came in at $0.05 , up from $0.03 a year ago and ahead of the roughly $0.03 consensus estimate.
Net sales fell to $836 million , down 7.5% year over year (7% on a constant-currency basis) and below the roughly $859 million consensus estimate. Adjusted earnings per share (EPS) came in at $0.29 , missing the $0.31 consensus and down from $0.37 in the prior-year quarter.
Warby Parker reported third quarter 2026 revenue of $244.7 million , up 10.4% year over year and roughly in line with consensus estimates of about $244.9 million. GAAP (generally accepted accounting principles) diluted earnings per share (EPS) came in at $0.04 , above the consensus estimate of $0.03.
Pulse Biosciences reported third-quarter 2026 revenue of $0.4 million, below the consensus estimate of roughly $0.52 million but up from $0.1 million a year earlier. GAAP net loss widened to $23.1 million, or $0.32 per share, versus a consensus loss of $0.29 per share and a $19.4 million loss in the prior-year quarter.
ICU Medical reported fourth-quarter 2025 revenue of $540.7 million, down roughly 14% year over year, reflecting the May 2025 divestiture of its IV Solutions business into a joint venture. Adjusted diluted earnings per share (EPS) came in at $1.91, above the consensus estimate of about $1.71, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $98.2 million.
Teleflex reported third-quarter revenue from continuing operations of $567.8 million , up 0.2% year over year on a reported basis and 3.0% on a pro forma adjusted constant-currency basis. Adjusted diluted earnings per share (EPS) from continuing operations rose to $2.63 , up 39.2% from $1.89 in the prior-year period and ahead of management's expectations.
Solventum reported third-quarter 2026 revenue of $1.95 billion, down 7% year over year but modestly above the $1.93 billion consensus estimate. Adjusted earnings per share (EPS, a company's profit divided by its outstanding shares) came in at $1.45, beating analysts' consensus of $1.34 by roughly 8%.
BD reported fourth-quarter fiscal 2026 revenue of $5.274 billion , up 5.4% year over year (5.6% on a currency-neutral basis), exceeding analyst estimates. Adjusted earnings per share (EPS) reached $4.15 , up 27.3% year over year and ahead of consensus expectations of roughly $4.07 to $4.11.
WRBY gapped up in premarket and extended higher during the regular session, jumping from a $21.29 prior close to about $26.41, a gain of +24.05%. Warby Parker reported Q3 2026 results before the open, beating adjusted EBITDA ($28.6M vs $26.9M consensus), topping GAAP EPS estimates ($0.04 vs $0.03), raising full-year revenue guidance, and announcing November 12 pre-orders for its Intelligent Eyewear collection.
Third quarter 2026 net sales were $83.4 million, down 12% year over year, but the decline reflects a difficult comparison to $25.9 million in deferred China sales recognized a year earlier. Excluding that one-time item, total revenue grew 21%, led by 31% growth in China and strong double-digit gains in the Europe, Middle East, and Africa (EMEA) region.
Envista Holdings reported third quarter 2026 sales of $691.5 million , up 3.2% year over year and essentially in line with Wall Street's consensus estimate of roughly $688 million. Adjusted earnings per share (EPS) came in at $0.40 , beating the consensus estimate of $0.36 by about 12% and up from $0.32 in the prior-year quarter.
Medline reported third-quarter 2026 net sales of $7.86 billion , up 10.4% year over year, with organic sales up 10.5%. Adjusted diluted EPS (earnings per share) came in at $0.44 , above the consensus estimate of $0.35.
OrthoPediatrics (KIDS) is a pediatric orthopedic device specialist posting double-digit revenue growth and rising guidance, while DENTSPLY Sirona (XRAY) is a global dental equipment and consumables maker working through a turnaround marked by softer growth and leadership transitions. Tickeron AI Verdict: KIDS. Trend consistency, stronger relative momentum, and an improving profitability and cash-flow trajectory currently favor OrthoPediatrics over DENTSPLY Sirona in this head-to-head stock comparison.
The central price target of $68 is the arithmetic mean of the six verified analyst price targets currently above the latest closing price of $60.41 for AtriCure (Nasdaq: ATRC). The overall average of all valid analyst targets is lower—near $57.56—which is below the current price, so the $68 figure reflects only the targets that sit above the stock's latest close.